|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics. CA Cancer J Clin. 60:277–300. 2010.
|
|
2
|
Muller A, Homey B, Soto H, et al:
Involvement of chemokine receptors in breast cancer metastasis.
Nature. 410:50–56. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moore MA: The role of chemoattraction in
cancer metastases. Bioessays. 23:674–676. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jones DH, Nakashima T, Sanchez OH, et al:
Regulation of cancer cell migration and bone metastasis by RANKL.
Nature. 440:692–696. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Roodman GD: Mechanisms of bone metastasis.
N Engl J Med. 350:1655–1664. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yasuda H, Shima N, Nakagawa N, et al:
Osteoclast differentiation factor is a ligand for
osteoprotegerin/osteoclastogenesis-inhibitory factor and is
identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 95:3597–3602.
1998. View Article : Google Scholar
|
|
7
|
Lacey DL, Timms E, Tan HL, et al:
Osteoprotegerin ligand is a cytokine that regulates osteoclast
differentiation and activation. Cell. 93:165–176. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Keller ET: The role of osteoclastic
activity in prostate cancer skeletal metastases. Drugs Today
(Barc). 38:91–102. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thomas RJ, Guise TA, Yin JJ, et al: Breast
cancer cells interact with osteoblasts to support osteoclast
formation. Endocrinology. 140:4451–4458. 1999.PubMed/NCBI
|
|
10
|
Hsu H, Lacey DL, Dunstan CR, et al: Tumor
necrosis factor receptor family member RANK mediates osteoclast
differentiation and activation induced by osteoprotegerin ligand.
Proc Natl Acad Sci USA. 96:3540–3545. 1999. View Article : Google Scholar
|
|
11
|
Nakagawa N, Kinosaki M, Yamaguchi K, et
al: RANK is the essential signaling receptor for osteoclast
differentiation factor in osteoclastogenesis. Biochem Biophys Res
Commun. 253:395–400. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mikami S, Katsube K, Oya M, et al:
Increased RANKL expression is related to tumour migration and
metastasis of renal cell carcinomas. J Pathol. 218:530–539. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Armstrong AP, Miller RE, Jones JC, Zhang
J, Keller ET and Dougall WC: RANKL acts directly on RANK-expressing
prostate tumor cells and mediates migration and expression of tumor
metastasis genes. Prostate. 68:92–104. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen LM, Kuo CH, Lai TY, et al: RANKL
increases migration of human lung cancer cells through
intercellular adhesion molecule-1 up-regulation. J Cell Biochem.
112:933–941. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Santini D, Perrone G, Roato I, et al:
Expression pattern of receptor activator of NFkB (RANK) in a series
of primary solid tumors and related bone metastases. J Cell
Physiol. 226:780–784. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hiscox S, Jordan NJ, Morgan L, Green TP
and Nicholson RI: Src kinase promotes adhesion-independent
activation of FAK and enhances cellular migration in
tamoxifen-resistant breast cancer cells. Clin Exp Metastasis.
24:157–167. 2007. View Article : Google Scholar
|
|
17
|
Meng XN, Jin Y, Yu Y, et al:
Characterisation of fibronectin-mediated FAK signalling pathways in
lung cancer cell migration and invasion. Br J Cancer. 101:327–334.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Summy JM and Gallick GE: Src family
kinases in tumor pro gression and metastasis. Cancer Metastasis
Rev. 22:337–358. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sabbota AL, Kim HRC, Zhe X, Fridman R,
Bonfil RD and Cher ML: Shedding of RANKL by tumor-associated
MT1-MMP activates Src-dependent prostate cancer cell migration.
Cancer Res. 70:5558–5566. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Myoui A, Nishimura R, Williams PJ, et al:
c-Src tyrosine kinase activity is associated with tumor
colonization in bone and lung in an animal model of human breast
cancer metastasis. Cancer Res. 63:5028–5033. 2003.PubMed/NCBI
|
|
21
|
Zhang XH, Wang Q, Gerald W, et al: Latent
bone metastasis in breast cancer tied to Src-dependent survival
signals. Cancer Cell. 16:67–78. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Riaz M, Elstrodt F, Hollestelle A, Dehghan
A, Klijn JG and Schutte M: Low-risk susceptibility alleles in 40
human breast cancer cell lines. BMC Cancer. 9:2362009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kenny P, Lee G, Myers C, et al: The
morphologies of breast cancer cell lines in three-dimensional
assays correlate with their profiles of gene expression. Mol Oncol.
1:84–96. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gan Y, Shi C, Inge L, Hibner M, Balducci J
and Huang Y: Differential roles of ERK and Akt pathways in
regulation of EGFR-mediated signaling and motility in prostate
cancer cells. Oncogene. 29:4947–4958. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jiang Q, Zhou C, Bi Z and Wan Y:
EGF-induced cell migration is mediated by ERK and PI3K/AKT pathways
in cultured human lens epithelial cells. J Ocul Pharmacol Ther.
22:93–102. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hwang YP, Yun HJ, Choi JH, et al:
Suppression of EGF-induced tumor cell migration and matrix
metalloproteinase-9 expression by capsaicin via the inhibition of
EGFR-mediated FAK/Akt, PKC/Raf/ERK, p38 MAPK, and AP-1 signaling.
Mol Nutr Food Res. 55:594–605. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Darnay BG, Haridas V, Ni J, Moore PA and
Aggarwal BB: Characterization of the intracellular domain of
receptor activator of NF-κB (RANK). Interaction with tumor necrosis
factor receptor-associated factors and activation of NF-kB and
c-Jun N-terminal kinase. J Biol Chem. 273:20551–20555. 1998.
|
|
28
|
Chen T and Feng X: Cell-based assay
strategy for identification of motif-specific RANK signaling
pathway inhibitors. Assay Drug Dev Technol. 4:473–482. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Darnay BG, Ni J, Moore PA and Aggarwal BB:
Activation of NF-κB by RANK requires tumor necrosis factor
receptor-associated factor (TRAF) 6 and NF-κB-inducing kinase.
Identification of a novel TRAF6 interaction motif. J Biol Chem.
274:7724–7731. 1999.
|
|
30
|
Lee SY, Reichlin A, Santana A, Sokol KA,
Nussenzweig MC and Choi Y: TRAF2 is essential for JNK but not NF-κB
activation and regulates lymphocyte proliferation and survival.
Immunity. 7:703–713. 1997.
|
|
31
|
Santini D, Schiavon G, Vincenzi B, et al:
Receptor activator of NF-κB (RANK) expression in primary tumors
associates with bone metastasis occurrence in breast cancer
patients. PLoS One. 6:e192342011.
|
|
32
|
Fizazi K, Carducci M, Smith M, et al:
Denosumab versus zoledronic acid for treatment of bone metastases
in men with castration-resistant prostate cancer: a randomised,
double-blind study. Lancet. 377:813–822. 2011. View Article : Google Scholar
|
|
33
|
Stopeck AT, Lipton A, Body JJ, et al:
Denosumab compared with zoledronic acid for the treatment of bone
metastases in patients with advanced breast cancer: a randomized,
double-blind study. J Clin Oncol. 28:5132–5139. 2010. View Article : Google Scholar
|
|
34
|
Lipton A, Steger GG, Figueroa J, et al:
Randomized active-controlled phase II study of denosumab efficacy
and safety in patients with breast cancer-related bone metastases.
J Clin Oncol. 25:4431–4437. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rifkin WD: Denosumab in postmenopausal
women with low bone mineral density. N Engl J Med. 354:2390–2391;
author reply 2390–2391. 2006. View Article : Google Scholar
|
|
36
|
Onishi T, Hayashi N, Theriault RL,
Hortobagyi GN and Ueno NT: Future directions of bone-targeted
therapy for metastatic breast cancer. Nat Rev Clin Oncol.
7:641–651. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mayer EL and Krop IE: Advances in
targeting SRC in the treatment of breast cancer and other solid
malignancies. Clin Cancer Res. 16:3526–3532. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Araujo J and Logothetis C: Targeting Src
signaling in metastatic bone disease. Int J Cancer. 124:1–6. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Saad F and Lipton A: SRC kinase
inhibition: targeting bone metastases and tumor growth in prostate
and breast cancer. Cancer Treat Rev. 36:177–184. 2010. View Article : Google Scholar : PubMed/NCBI
|
